SOLIGENIX, INC.
About SOLIGENIX, INC.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $119.4K
- Net income
- -$11.1M
- Total assets
- $9.2M
- Market cap
- $6.6M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $6.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 5, 1994
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review SOLIGENIX, INC..
